MedTrace Logo

Does Deep Neuromuscular Blockade Improve Operating Conditions During Total Hip Replacements?

NCT03219294 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 116

Last updated 2019-09-18

Study results available
· View outcomes & findings →

Summary

During many surgeries, increased muscle tension makes it harder for the surgeon to expose the site of surgery and work within the incision. Neuromuscular blockade (NMB) drugs such as Vecuronium bind to neurotransmitter (acetyl choline) receptors at the neuromuscular junction, blocking their action and producing muscle relaxation. This muscle relaxation allows easier retraction of muscle tissues and manipulation of structures in the wound. Improved surgical conditions are likely to result in improved patient outcomes. While increased depths of NMB have been shown to optimize surgical conditions during intra-abdominal and retroperitoneal procedures, the impact of NMB depth has not been reported for orthopedic surgeries.1 To address this, we propose to study the effect of NMB depth on surgical conditions during total hip replacement (THR).

Conditions

  • Arthropathy of Hip

Interventions

DRUG

Vecuronium 0.1 mg/kg

Vecuronium will be administered to achieve and maintain 1 to 2 TOF contractions.

DRUG

Vecuronium 0.2mg/kg

Vecuronium will be administered to achieve and 0 TOF/PTC 1-2.

Sponsors & Collaborators

  • MaineHealth

    collaborator OTHER

  • Spectrum Medical Group Anesthesiology

    collaborator OTHER

  • Craig Curry

    lead OTHER

Principal Investigators

  • Craig Curry, MD · Maine Medical Center/Spectrum Medical Group

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-01
Primary Completion
2018-04-30
Completion
2018-05-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03219294 on ClinicalTrials.gov